UCBC is the first cancer center in Georgia to offer Theranostics treatment outside of a hospital setting.
What is Theranostics?
Theranostics is a personalized approach to treating cancer, using both diagnostics (imaging) and therapy tools as part of the treatment. Custom Theranostic treatment plans can be devised that are unique to each individual, ensuring that the most effective treatment is administered at the right time.
How does it work?
Theranostics uses PET scan imaging to see if specific targets, known as tumor receptors, are present on tumor cells. If these targets are present and visible on the scan, a radioactive drug is used to treat the tumors. The drug is given as an injection and selectively targets the tumor cells with precision while avoiding healthy areas.
What types of Theranostics treatments do we offer?
Currently, UCBC is treating adults with Gastroenteropancreatic Neuroendocrine Tumors, also known as GEP NETs” or “neuroendocrine tumor” or “neuroendocrine cancer”, and also men with prostate cancer.
LUTATHERA®
LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.
Xofigo®
Xofigo® (radium Ra 223 dichloride) injection is used to treat prostate cancer that no longer responds to hormonal or surgical treatment that lowers testosterone. It is for men whose prostate cancer has spread to the bone with symptoms but not to other parts of the body.
Pluvicto®
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with other anticancer treatments. Pluvicto® is a targeted radioligand therapy.
